Verona Pharma Set to Share Q3 2024 Results and Insights
Overview of Upcoming Financial Results
Verona Pharma plc (NASDAQ: VRNA) is gearing up to release its financial results for the third quarter, concluding on September 30, 2024. The scheduled announcement will take place on November 4, 2024. This event is crucial for investors and stakeholders looking to understand the company’s financial health and strategic direction.
Conference Call Details
On the day of the report, Verona Pharma will host a conference call at 9:00 a.m. EDT (2:00 p.m. GMT). This forum will provide an excellent opportunity for the investment community to glean insights directly from the company's leadership regarding their financial performance and future strategies. Interested participants can join by dialing in on either of the following numbers:
- For callers in the United States: +1-833-816-1396
- For international callers: +1-412-317-0489
Live Webcast Accessibility
For those unable to participate via phone, Verona Pharma will provide a live webcast that can be accessed from the Events and Presentations section on their official website. A recording of the call will be available for playback for up to 90 days following the event, ensuring that interested parties can stay informed at their convenience.
Contact Information for Inquiries
For any additional information about the conference call or the upcoming financial report, interested stakeholders can reach out to:
Verona Pharma plc
Phone: +1-844-341-9901
Victoria Stewart, Senior Director of Investor Relations and Communications
Email: [email protected]
Argot Partners
US Investor Inquiries
Phone: +1-212-600-1902
Email: [email protected]
Ten Bridge Communications
International / US Media Inquiries
Phone: +1-312-523-5016
Email: [email protected]
About Verona Pharma
Verona Pharma is a forward-thinking biopharmaceutical company dedicated to innovating and commercializing groundbreaking therapies for chronic respiratory diseases. Its flagship product, Ohtuvayre™ (ensifentrine), is significant as it represents the first inhaled therapy that merges both bronchodilator and non-steroidal anti-inflammatory effects in a singular solution. This dual-action mechanism presents a promising option not only for the treatment of Chronic Obstructive Pulmonary Disease (COPD) but also for a variety of other respiratory conditions, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and asthma. The ongoing development work positions Verona Pharma to address critical unmet needs in respiratory healthcare.
For further insights, interested parties can explore more on the company's endeavors by visiting Verona Pharma's website.
Frequently Asked Questions
What is the date for Verona Pharma's Q3 2024 results announcement?
Verona Pharma will announce its Q3 2024 financial results on November 4, 2024.
What time will the conference call take place?
The conference call is scheduled for 9:00 a.m. EDT / 2:00 p.m. GMT.
How can I listen to the conference call?
You can join the conference call by dialing the respective numbers for US and international callers or by accessing the live webcast on their official website.
Who can I contact for more information?
For further information, you can contact Verona Pharma directly at +1-844-341-9901 or via email.
What is Ohtuvayre™?
Ohtuvayre™ (ensifentrine) is Verona Pharma's first commercial product designed to treat COPD by providing both bronchodilation and anti-inflammatory benefits in one inhaled therapy.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Astex Pharmaceuticals Unveils Promising Data at Major Symposium
- InterDigital Partners with UT Austin to Advance AI in Wireless Tech
- Niu Technologies Prepares to Release Q3 2024 Financials
- New Innovations Unveiled at the 2024 Smart City Expo
- MYCOM OSI Welcomes New Leaders: Andrew Coll and Charles Bligh
- Innovative Partnership to Propel Sustainable Travel Forward
- Global Fashion Summit Debuts in China to Promote Sustainability
- Sustainability Takes Center Stage at Global Fashion Summit 2024
- Eckoh Plc and Investec Bank: Insights on Recent Dealings
- ISS A/S Commences New Phase of Share Buyback Initiative
Recent Articles
- Surging Bitcoin Whales Reactivate After Years of Dormancy
- Investor Insights: Ross Gerber on Waymo's Robotaxi Strategy
- Naspers CEO Reflects on Initial 100 Days in Leadership Role
- U.S. Stock Markets Surge as Investors Embrace Positive Sentiments
- Exceptional Q3-2024 Results: A Bright Future for Serabi Gold
- Key Stocks to Monitor as the Week Begins
- Ionis Pharmaceuticals Seeks Approval for WAINZUA in Europe
- SciBase Enhances Market Presence at Key US Dermatology Event
- Examining Global Efforts to Achieve 2030 Biodiversity Goals
- Key Insights and Expectations for COP16 Biodiversity Summit
- Taiwan Stock Market Experiences Notable Gains
- ViaNautis Welcomes Ray Jupp as Their New Chief Scientific Officer
- Tulikivi Corporation Welcomes Mikko Kuoppa to Management Team
- Foresight VCT plc Updates on Significant Share Transactions
- Vast Resources plc Shares Progress on Q2 2024 Production
- RIBER Expands GaN Production With New MBE 49 System Order
- Serabi Gold plc Reports Record Production for Q3-2024
- Why Investing in ON Semiconductor Could be Your Best Move
- Statkraft Pursues Major Offshore Wind Initiative in Sweden
- Michelin's Strategic Share Buyback Initiative Explained
- Subsea7 Announces Recent Share Repurchase Activity Details
- PayPoint's Recent Share Buyback Enhances Investor Confidence
- ICG Enterprise Trust plc's Strategic Buyback of Shares
- European Energy A/S Launches Tender Offer for Green Bonds
- JDE Peet's Welcomes Rafael Oliveira as New CEO
- Verona Pharma's Upcoming Financial Disclosure and Updates
- European Energy A/S Announces Conditional Early Bond Redemption
- Exor N.V. Updates on Recent Share Buyback Activities
- Smiths Detection Achieves Unique Certification for Security Tech
- eLstar Dynamics Introduces Revolutionary Dynamic Glass at Glasstec
- Agilent Unveils Innovative Infinity III LC Series for HPLC
- Faraday Future Launches a Creative Contest for FX Logo Design
- Seaport Therapeutics Successfully Raises $225 Million in Series B
- JAB Boosts JDE Peet’s Free Float Through Strategic Share Moves
- Seaport Therapeutics Secures $225 Million to Advance Mental Health Treatments
- Lazard Welcomes Fabien Antignac to Lead European Debt Solutions
- Great Bay Bio's Revolutionary Drug Development Ecosystem Unveiled
- Akkodis Achieves Zinnov Leader Status for Digital Engineering
- BWH Hotels and Mews: A Transformative Partnership for Innovation
- McDermott Achieves Platinum Status in Garnet Recycling Leadership
- Thunes Empowers Banks with Mobile Wallet Payment Solutions
- YogaEasy Unveils Exciting New Online Platform for Yoga Lovers
- Rockit Global's Partnership with Kung Fu Panda: A Delightful Venture
- Akkodis Awarded as Leader in ER&D and Digital Engineering
- Dr. Joleen Liang: Leading the AI Transformation in Education
- Tan Dun: Journey from Hunan Villager to Global Music Icon
- DNB's Strategic Acquisition of Carnegie Valued at $1.14 Billion
- Bitcoin Soars to $69K: Trump Speculation Fuels Cryptocurrency Rise
- Unlocking Financial Growth: Top ETFs for Lifelong Investments
- Insights from Fabricio Bloisi on Prosus' Vision and Growth